An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases (A-337)

An Exploratory Study of A-337 in the Management of Malignant Solid Dose

Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

Study Overview

• Status: Not yet recruiting
• Conditions: Recurrent or Metastatic Solid Tumors
• Intervention / Treatment: Biological: Recombinant Anti-EpCAM-CD3 Antibody Injection

Detailed Description

Protocol Number: IM-2021A Study Stage: Phase I Study Number: 2-3 sites Subject Number: up to 94 patients with recurrent or metastatic solid tumors, for whom there are no available effective standard treatments or for whom standard treatments have proven ineffective or intolerable.

• Study Type: Interventional
• Enrollment (Estimated): 94
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Darong Dai, Bachelor; Phone Number: 8618284820495; Email: darong.dai@itabmed.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18-75 years, all genders
• Patients with histologically or cytologically confirmed advanced malignant solid tumors who have failed standard treatment, have no standard treatment options, or are not suitable for standard treatment at this stage.
• The interval between the first dose of investigational drug and previous major surgery, medical device treatment, or local radiotherapy was at least 28 days. At least 21 days between the first dose of investigational drug and previous cytotoxic chemotherapy, immunotherapy, or biological agents; At least 14 days between he first dose of investigational drug and previous tumor-related endocrinotherapy and minor surgery; The interval between he first dose of investigational drug and small molecule targeted drugs was at least 21 days or 5 half-lives, whichever is longer; At least 14 days interval between the first dose of investigational drug and antineoplastic chinese traditional medicines.
• Patients with at least one measurable lesion on the basis of RECIST v1.1.
• ECOG ≤ 1
• Patients are willing to provide archival tumor tissue or undergo fresh tissue biopsy.
• Life expectancy is at least 3 months.

• Having adequate organ and bone marrow functional reserve, defined as follows:

  1. Blood routine (corrected with no growth factor support, blood transfusion, or other medication within 2 weeks before screening) ANC ≥ 1.5 ×109 /L,PLT≥ 75×109/L,HGB≥ 90 g/L
  2. hepatic parameters :TBIL ≤ 1.5 × ULN For patients with liver metastases or a history of Gilbert's syndrome/suspected disease,TBIL ≤ 3 ×ULN For patients without liver metastases,ALT≤ 2.5 ×ULN,AST≤ 2.5 ×ULN For patients with liver metastases,ALT or AST ≤ 5 ×ULN
  3. renal function:Cr≤ 1.5×ULN or CrCl≥ 45 mL/min (using The Cockcroft-Gault formula )
  4. coagulation function:APTT≤ 1.5 × ULN,INR≤ 1.5 × ULN. Patients who were in the therapeutic window for long-term use of anticoagulants who did not meet these criteria could be enrolled at the investigator's discretion.
• Participants are capable of providing written informed consent and adhering to the protocol.

Exclusion Criteria:

• Past or present malignant tumor diagnosed in the past 3 years and/or required treatment.Except for the completely resected basal and squamous cell skin cancers and any type in situ.
• Patients with CNS metastases, unless the metastases were treated and stable for at least 4 weeks and without taking systemic steroids ≥ 10 mg prednisone/day or equivalent.

• Patients suspected or confirmed immunocompromised:

  1. Patients with HIV
  2. Patients requiring systemic or local treatment with systemic steroids or any immunomodulatory drug (at a level that results in a systemic dose effect).E.g. High-dose oral or intravenous steroids > 10 mg/ day prednisone or its equivalent, or methotrexate > 15 mg once weekly).Allow topical, inhaled or topical use of steroids (at levels not thought to cause systemic dose effects);
  3. Patients with active autoimmune disease or a history of autoimmune disease with potential recurrence(e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autohemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis).Exceptions are patients with type I diabetes, hypothyroidism that is manageable with hormone-replacement therapy, skin conditions (e.g., vitiligo, psoriasis, or alopecia) that require no systemic treatment, or childhood asthma/allergies that have resolved without any intervention in adulthood.
  4. Patients with allogeneic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation)
  5. Any other condition that was considered by the investigator to place the patient at unacceptable risk as a result of receiving immunomodulatory therapy.

• Anticancer therapy, including hormonal therapy, biological therapy, cellular therapy, or radiation therapy, was administered within 4 weeks prior to the initiation of study treatment, except in the following cases:

  1. Hormonal therapy for prostate cancer using gonadotropin-releasing hormone (GnRH) agonists.
  2. Hormone replacement therapy or oral contraceptives

• Participants with any disease, medical condition, or social factor that was judged by the investigator to be likely to affect the study results or adherence were excluded from the study according to the protocol:

  1. Uncontrolled acute infection or confirmed bacteremia.
  2. Patients with HIV or HBV,and HBV copy number > 1000/mL or HBV DNA titer > 200 IU/mL.And patients with HCV.
  3. Severe dyspnea, pulmonary insufficiency, or continuous oxygen therapy.
  4. The patients were classified as New York Heart Association (NYHA) class 3 or 4 or left ventricular ejection fraction (LVEF) < 50%.
  5. Myocardial infarction, unstable angina, stroke, or transient ischemic attack, or other cardiovascular events of grade III or higher, occurred within 6 months before dose administration.
  6. Severe arrhythmia or uncontrolled hypertension (systolic blood pressure > 180 mmHg and diastolic blood pressure > 100 mmHg) or diabetes mellitus.
• Patients with uncontrolled systemic infection.
• Patients with positive treponema pallidum antibody.
• Patients who had undergone major surgical procedures (craniotomy, thoracotomy, or laparotomy) or who had nonhealed wounds, ulcers, or fractures within 4 weeks before the administration of the first dose of investigational drug, with the exception of needle biopsy procedures.
• Patients with alcohol or drug dependence.
• Patients with mental disorders, including epilepsy or dementia, or poor adherence.
• Patients with tumor types of nonepithelial origin.
• Patients with received an EpCAM antibody class, CD3 dual antibody class, or CAR-T therapy.
• Patients who did not recover to grade 1 or less toxicity (CTCAE 5.0) from previous antineoplastic therapy(except alopecia) .Patients who did not recover to grade 1 or below (CTCAE 5.0) after radiotherapy (except no effect).
• Pregnant (positive pregnancy test), lactating women.Women of childbearing age who did not agree to use contraception for at least 3 months after signing the informed consent form until the end of the study.Women of childbearing age had a positive HCG test within 7 days before the first day of treatment.
• Male subjects who did not agree to use contraception for at least 3 months after signing the informed consent form until the end of the study (except surgical sterilization)
• Patients with a allergy to the study drug or its excipients.
• Patients who were deemed by the investigator to be ineligible for this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: single arm; A-337dosage: 0.05, 0.15, 0.3, 0.6, 0.9, 1.2, 1.5 μg/kg/d	Biological: Recombinant Anti-EpCAM-CD3 Antibody Injection; Intravenous Infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the Incidence and Characteristics of Adverse Events of A-337 in the Treatment of malignant Solid Tumors	Incidence and characteristics of adverse events	At the end of Cycle 1 (each cycle is 28 days)
Evaluate the MTD and DLT of A-337 in the Treatment of malignant Solid Tumors	dose limited toxicity(DLT), maximum tolerance dose(MTD)	At the end of Cycle 1 (each cycle is 28 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the PK(Cmax) of A-337 in the Treatment of malignant Solid Tumors	Cmax	At the end of Cycle 3 (each cycle is 28 days)
Evaluate the PK(Tmax) of A-337 in the Treatment of malignant Solid Tumors	Tmax	At the end of Cycle 3 (each cycle is 28 days)
Evaluate the PK（T1/2) of A-337 in the Treatment of malignant Solid Tumors	T1/2	At the end of Cycle 3 (each cycle is 28 days)
Evaluate the PK(Vd) of A-337 in the Treatment of malignant Solid Tumors	Vd	At the end of Cycle 3 (each cycle is 28 days)
Evaluate the PK(CL/F) of A-337 in the Treatment of malignant Solid Tumors	CL/F	At the end of Cycle 3 (each cycle is 28 days)
Evaluate the PK(MRT) of A-337 in the Treatment of malignant Solid Tumors	MRT	At the end of Cycle 3 (each cycle is 28 days)
Evaluate the PK(AUC) of A-337 in the Treatment of malignant Solid Tumors	AUC	At the end of Cycle 3 (each cycle is 28 days)
Evaluate the efficacy evaluation（ORR） of A-337 in the Treatment of malignant Solid Tumors	ORR	At the end of each Cycle (each cycle is 28 days)
Evaluate the efficacy evaluation（DCR） of A-337 in the Treatment of malignant Solid Tumors	DCR	At the end of each Cycle (each cycle is 28 days)
Evaluate the efficacy evaluation（DDC） of A-337 in the Treatment of malignant Solid Tumors	DDC	At the end of each Cycle (each cycle is 28 days)
Evaluate the efficacy evaluation（PFS） of A-337 in the Treatment of malignant Solid Tumors	PFS	At the end of each Cycle (each cycle is 28 days)
Evaluate the efficacy evaluation（OS） of A-337 in the Treatment of malignant Solid Tumors	OS	At the end of each Cycle (each cycle is 28 days)

Collaborators and Investigators

• Sponsor: ITabMed Co., Ltd.
• Investigators: Principal Investigator: Qinghua Zhou, Doctor, West China Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2023
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: October 10, 2023
• First Submitted That Met QC Criteria: October 17, 2023
• First Posted (Actual): October 23, 2023

Study Record Updates

• Last Update Posted (Actual): October 23, 2023
• Last Update Submitted That Met QC Criteria: October 17, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Antibodies
• Other Study ID Numbers: IM-2021A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No